Biotechnology company Compass Pathways plc (Nasdaq:CMPS) announced on Tuesday that its COMP360 psilocybin formulation met the primary endpoint in the Phase 3 COMP006 trial, demonstrating a statistically significant and clinically meaningful reduction in Montgomery-Åsberg Depression Rating Scale scores at Week 6 versus a 1 mg comparator.
Two 25 mg doses delivered three weeks apart produced a mean treatment difference of −3.8 points (p
Nucleome Therapeutics names new chief scientific officer
Celltrion data show subcutaneous infliximab restores disease control after treatment interruption
Cambridge Cognition expands into India through Ivory commercialisation agreement
Genentech reports positive Phase III MAJESTYdata for Gazyva in primary membranous nephropathy
Ella immunoassay platform gains CE‑IVD approval in the EU
HanchorBio's HCB101 receives US FDA Orphan Drug Designation in gastric cancer
MEDIPOST files IND amendment to start Phase III trial for knee osteoarthritis therapy
AstraZeneca reports positive Phase III results for BREZTRI in uncontrolled asthma
Centivax Inc doses first healthy volunteers in Centi-Flu 01 Phase 1A clinical trial
Amgen wins European approval for Uplizna in generalised myasthenia gravis